A5037356234- Psoriasis: Treatment and Pathogenesis
- Atherosclerosis and Cardiovascular Diseases
- Systemic Lupus Erythematosus Research
- Adipokines, Inflammation, and Metabolic Diseases
- Vitamin D Research Studies
- Cardiovascular Disease and Adiposity
- Lipoproteins and Cardiovascular Health
- Spondyloarthritis Studies and Treatments
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Systems, Economic Evaluations, Quality of Life
- Dermatology and Skin Diseases
- Cardiac Imaging and Diagnostics
- Rheumatoid Arthritis Research and Therapies
- Vitamin C and Antioxidants Research
- Cytokine Signaling Pathways and Interactions
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cerebrovascular and Carotid Artery Diseases
- Adipose Tissue and Metabolism
- Fatty Acid Research and Health
- Lipid metabolism and disorders
- Asthma and respiratory diseases
- Genetic Associations and Epidemiology
- Biomarkers in Disease Mechanisms
- Liver Disease Diagnosis and Treatment
- HIV-related health complications and treatments
University of California, San Diego
2025
Paras Hospitals
2025
National Institutes of Health
2015-2024
National Heart Lung and Blood Institute
2015-2024
The Retina Center
2024
Jacobs (United States)
2024
George Washington University
2017-2024
Washington University Medical Center
2023-2024
Abcentra (United States)
2024
University of Pennsylvania
2009-2023
<h3>Objectives</h3> We aimed to quantify the risk of major adverse cardiovascular events (MACE) among patients with psoriatic arthritis (PsA), rheumatoid (RA) and psoriasis without known PsA compared general population after adjusting for traditional factors. <h3>Methods</h3> A population-based longitudinal cohort study from 1994 2010 was performed in The Health Improvement Network (THIN), a primary care medical record database UK. Patients aged 18–89 years age PsA, RA or were included. Up...
Despite the growing literature on comorbidity risks in psoriasis, there remains a critical knowledge gap degree to which objectively measured psoriasis severity may affect prevalence of major medical comorbidity.OBJECTIVE To examine patients with mild, moderate, or severe classified based body surface area involvement, compared that without psoriasis.DESIGN, SETTING, AND PARTICIPANTS Population-based cross-sectional study patient data from United Kingdom-based electronic records; analysis...
An emerging model of metabolic syndrome and type 2 diabetes is adipose dysfunction with leukocyte recruitment into leading to chronic inflammation insulin resistance (IR). This study sought explore potential mechanisms inflammatory-induced IR in humans a focus on tissue.We performed 60-h endotoxemia protocol (3 ng/kg intravenous bolus) healthy adults (n = 20, 50% male, 80% Caucasian, aged 27.3 +/- 4.8 years). Before after endotoxin, whole-blood sampling, subcutaneous biopsies, frequently...
Abstract Aims The neutrophil–lymphocyte ratio (NLR) is a readily available inflammatory biomarker that may associate with atherosclerosis and predict cardiovascular (CV) events. aims of this study are to determine whether the NLR predicts incident major adverse events (MACE) modified by anti-inflammatory therapy. Methods results Baseline on-treatment NLRs were calculated from complete blood counts among 60 087 participants randomized in CANTOS, JUPITER, SPIRE-1, SPIRE-2, CIRT trials receive...
The use of biologic therapy has increased over the past decade well beyond primary autoimmune diseases. Indeed, a recent trial using an anti-IL-1beta antibody reduced second myocardial infarction (MI) in those who have had MI. Psoriasis is chronic inflammatory disease often treated with biologics when severe, associated risk MI, part driven by high-risk coronary plaque phenotypes computed tomography angiography (CCTA). We hypothesized that we would observe reduction inflammatory-driven...
Neutrophil dysregulation is implicated in the pathogenesis of systemic lupus erythematosus (SLE). SLE characterized by elevated levels a pathogenic neutrophil subset known as low-density granulocytes (LDGs). The origin and phenotypic, functional, heterogeneity LDGs remain to be systematically determined. Transcriptomics epigenetic assessment LDGs, autologous normal-density neutrophils, healthy control neutrophils was performed bulk single-cell RNA sequencing assay for transposase-accessible...
Psoriasis increases the risk of cardiovascular (CV) disease. Secukinumab, a fully human monoclonal antibody against IL-17A, shows significant efficacy in psoriasis, but effects on CV markers are unknown. CARIMA (Evaluation Cardiovascular Risk Markers Patients Treated with Secukinumab) was 52-week, randomized, double-blind, placebo-controlled, exploratory trial patients moderate to severe plaque psoriasis without clinical were randomly assigned receive 300 mg or 150 secukinumab until week 52...
Psoriasis is a chronic inflammatory skin disease associated with increased coronary plaque burden and cardiovascular events. Biologic therapy for psoriasis has been found to be favorably luminal plaque, but it unclear whether these associations are attributable direct anti-inflammatory effects on the arteries.To investigate association of biologic inflammation in patients using perivascular fat attenuation index (FAI), novel imaging biomarker that assesses by mapping spatial changes...
Abstract Increased risk of premature cardiovascular disease (CVD) is well recognized in systemic lupus erythematosus (SLE). Aberrant type I-Interferon (IFN)-neutrophil interactions contribute to this enhanced CVD risk. In animal models, the Janus kinase (JAK) inhibitor tofacitinib improves clinical features, immune dysregulation and vascular dysfunction. We conducted a randomized, double-blind, placebo-controlled trial SLE subjects (ClinicalTrials.gov NCT02535689). study, 30 are randomized...